Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status
Maintenance olaparib showed consistent clinical activity in the BRCAm and sBRCAm cohorts; exploratory analysis suggested similar activity in the non-BRCA HRRm cohort. These findings highlight that patients with PSR OC, beyond those with gBRCAm, may benefit from maintenance olaparib.
Authors
- Ana Fernández Montés (ORCID: https://orcid.org/0000-0003-4630-5830)
- Massimo Di Maïo (ORCID: https://orcid.org/0000-0001-8906-3785)
- Margarita Romeo (ORCID: https://orcid.org/0000-0003-1725-8115)
- Constanta Timcheva (ORCID: https://orcid.org/0000-0002-4245-7864)
- Radosław Mądry (ORCID: https://orcid.org/0000-0003-0738-2788)
- Zahid Bashir (ORCID: https://orcid.org/0000-0001-5546-1099)
- Geoff Hall (ORCID: https://orcid.org/0000-0002-8864-5932)
- Rosie Taylor
- Nicoletta Colombo (ORCID: https://orcid.org/0000-0002-4197-2506)
- Andrew R. Clamp (ORCID: https://orcid.org/0000-0002-4200-0186)
- Rosalind Margaret Glasspool (ORCID: https://orcid.org/0000-0002-5000-1680)
- Imre Pete
- Ana Herrero Ibáñez
- Jaroslav Klát (ORCID: https://orcid.org/0000-0001-9762-1345)
- Amit M. Oza (ORCID: https://orcid.org/0000-0002-9510-8641)
- David Cibula (ORCID: https://orcid.org/0000-0001-6387-9356)
- Alan Barnicle (ORCID: https://orcid.org/0000-0002-1475-7587)
- Beatriz Pardo (ORCID: https://orcid.org/0000-0002-8219-5483)
- Sandro Pignata (ORCID: https://orcid.org/0000-0002-8836-2633)
- Rumyana Ilieva
Institutions
- AstraZeneca (United Kingdom) (GB)
- Poznan University of Medical Sciences (PL)
- University of Ostrava (CZ)
- University of Milan (IT)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Charles University (CZ)
- Beatson West of Scotland Cancer Centre (GB)
- St James's University Hospital (GB)
- Princess Margaret Cancer Centre (CA)
- University of Manchester (GB)
- Medical University of Sofia (BG)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- University Hospital Ostrava (CZ)
- Hospital Universitario Miguel Servet (ES)
- National Institute of Oncology (HU)
- The Christie NHS Foundation Trust (GB)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Duran i Reynals Hospital (ES)
- Hospital Universitari Germans Trias i Pujol (ES)
- General University Hospital in Prague (CZ)
- University of Turin (IT)
- European Institute of Oncology (IT)
- University of Glasgow (GB)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1038/s41416-025-02966-x
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- AstraZeneca
- Merck Sharp and Dohme